1. Home
  2. HIG vs GMAB Comparison

HIG vs GMAB Comparison

Compare HIG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hartford Financial Services Group Inc. (The)

HIG

Hartford Financial Services Group Inc. (The)

SELL

Current Price

$137.13

Market Cap

33.7B

Sector

Finance

ML Signal

SELL

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

SELL

Current Price

$51.90

Market Cap

31.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
HIG
GMAB
Founded
1810
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.7B
31.9B
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
HIG
GMAB
Price
$137.13
$51.90
Analyst Decision
Hold
Strong Buy
Analyst Count
24
12
Target Price
★ $145.29
$65.01
AVG Volume (30 Days)
1.7M
★ 6.3M
Earning Date
10-26-2026
11-05-2026
Dividend Yield
★ 1.95%
N/A
EPS Growth
★ 28.70
N/A
EPS
★ 12.52
N/A
Revenue
★ $28,368,000,000.00
N/A
Revenue This Year
$2.00
$27.61
Revenue Next Year
$4.76
$21.18
P/E Ratio
$10.97
★ $1.90
Revenue Growth
★ 6.91
N/A
52 Week Low
$120.42
$23.62
52 Week High
$146.07
$59.97

Technical Indicators

Market Signals
Indicator
HIG
GMAB
Relative Strength Index (RSI) 57.06 60.69
Support Level $132.41 $25.91
Resistance Level $140.03 $59.97
Average True Range (ATR) 2.91 3.01
MACD 0.16 -0.68
Stochastic Oscillator 66.41 49.97

Price Performance

Historical Comparison
HIG
GMAB

About HIG Hartford Financial Services Group Inc. (The)

The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments, including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: